OncoMatch/Clinical Trials/NCT05072600
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
Is NCT05072600 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pembrolizumab for bladder cancer.
Treatment: Pembrolizumab — This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Excluded: Stage PN+
stage cT2-4N0M0，Urothelial carcinoma >50%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: tri-modality therapy — after maximum TURBT
Has received maximum TURBT followed by tri-modality therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)
Cannot have received: systemic anti-cancer therapy
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation
Cannot have received: radiotherapy
Exception: 1-week washout permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease
Has received prior radiotherapy within 2 weeks of start of study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify